Study Information

Alliance Study ID: A091101

NCT Study ID (ClinicalTrials.gov): NCT01711541

Alliance Committee: Experimental Therapeutics

Disease or Cancer Type: Head & Neck Cancers

Alliance Study Chair: Jonas De Souza

Status: COMPLETED


Study Description

This partially randomized phase I/II trial studies the side effects and best dose of veliparib when given together with combination chemotherapy and to see how well they work in treating patients with stage IV head and neck cancer. Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether combination chemotherapy is more effective when given with or without veliparib in treating head and neck cancer.

Related Publications

For publications related to this and other clinical trials, visit the Alliance Publications Application.

Data Sources & Contacts

Related Alliance Trials